Parallel Advisors LLC Decreases Stock Position in Colgate-Palmolive (NYSE:CL)

Parallel Advisors LLC lessened its stake in shares of Colgate-Palmolive (NYSE:CL) by 1.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 89,538 shares of the company’s stock after selling 910 shares during the quarter. Parallel Advisors LLC’s holdings in Colgate-Palmolive were worth $8,140,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CL. Kohmann Bosshard Financial Services LLC bought a new position in Colgate-Palmolive in the 4th quarter valued at $26,000. Centricity Wealth Management LLC bought a new position in Colgate-Palmolive in the 4th quarter valued at $27,000. Union Bancaire Privee UBP SA bought a new position in Colgate-Palmolive in the 4th quarter valued at $32,000. Briaud Financial Planning Inc bought a new position in Colgate-Palmolive in the 4th quarter valued at $32,000. Finally, Wintrust Investments LLC bought a new position in Colgate-Palmolive in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. UBS Group cut their price objective on Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 3rd. TD Cowen cut their price objective on Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $101.00 price target on shares of Colgate-Palmolive in a research report on Wednesday, January 29th. Barclays dropped their price target on Colgate-Palmolive from $96.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Finally, StockNews.com downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Colgate-Palmolive has an average rating of “Hold” and a consensus price target of $101.72.

Colgate-Palmolive Trading Down 0.8 %

Shares of NYSE:CL opened at $89.80 on Monday. Colgate-Palmolive has a 52-week low of $85.32 and a 52-week high of $109.30. The stock has a market cap of $72.87 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 4.20 and a beta of 0.40. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. The business has a 50-day moving average price of $89.02 and a 200-day moving average price of $94.67.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 31st. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.01. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. During the same period in the previous year, the business earned $0.87 earnings per share. Equities analysts predict that Colgate-Palmolive will post 3.75 EPS for the current year.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.